(Q69494944)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

title

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

author name string

T A Golper

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

D R Illingworth

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

C D Morris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

W M Bennett

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

publication date

1 April 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Kidney Diseases

2 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

page(s)

312-320

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

Hyperlipoproteinaemias in nephrotic syndrome

2 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Probability of Middle-Aged Men Developing Coronary Heart Disease in Five Years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

High-density lipoproteins in myocardial infarction survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Ischaemic heart-disease as a complication of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Effect of diet on serum lipoproteins in a population with a high risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Lipogenesis in aminonucleoside-induced nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Origin of hypercholesterolemia in chronic experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Hepatic Secretion of Lipoproteins in the Rat and the Effect of Experimental Nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Lipoproteins in experimental nephrosis: Plasma levels and composition

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Experimental nephrotic syndrome induced in the rat by puromycin aminonucleoside: hepatic synthesis of neutral lipids and phospholipids from 3H-water and 3H-palmitate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Increased hepatitic cholesterol production due to liver hypertrophy in rat experimental nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Plasma Triglyceride Metabolism in the Adult Nephrotic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Lipid and apolipoprotein levels in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

STUDIES ON THE METABOLISM OF THE SERUM PROTEINS AND LIPIDS IN A PATIENT WITH ANALBUMINEMIA

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Preclinical evaluation of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2889%2980038-1

7 January 2021

10.1016/S0272-6386(89)80038-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2650539%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

1 reference